LB Pharmaceuticals Financials

No, LB Pharmaceuticals (LBRX) reported a net income of -$25.2M in fiscal year 2025.

LB Pharmaceuticals (LBRX) reported diluted earnings per share of $-3.13 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

LB Pharmaceuticals (LBRX) has a return on equity of -8.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

LB Pharmaceuticals (LBRX) generated -$35.3M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

LB Pharmaceuticals (LBRX) generated -$35.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

LB Pharmaceuticals (LBRX) had $312.9M in total assets as of fiscal year 2025, including both current and long-term assets.

LB Pharmaceuticals (LBRX) invested $52K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

LB Pharmaceuticals (LBRX) invested $16.7M in research and development during fiscal year 2025.

LB Pharmaceuticals (LBRX) had 29M shares outstanding as of fiscal year 2025.

LB Pharmaceuticals (LBRX) had a current ratio of 41.44 as of fiscal year 2025, which is generally considered healthy.

LB Pharmaceuticals (LBRX) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

LB Pharmaceuticals (LBRX) had a return on assets of -8.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, LB Pharmaceuticals (LBRX) had $250.2M in cash against an annual operating cash burn of $35.2M. This gives an estimated cash runway of approximately 85 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

LB Pharmaceuticals (LBRX) has an earnings quality ratio of 1.40x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.